Cordis And Biosense In Merger Agreement
Cordis Corp, a Johnson & Johnson company, has reported that certain ofits affiliated companies have entered into a definitive merger agreement with Biosense, which specializes in medical sensor technology and is based in Haifa, Israel. The terms of the agreement were not disclosed.
Robert Croce, group chairman of J&J, said that the addition of Biosense strengthened the company's commitment to innovation in the field of cardiology and would help the group develop a full line of proprietary sensor technology products, which can be used to determine the exact location of medical instruments and enables the creation of 3-D and animated images, allowing instruments to be directed on a virtual image of the heart.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze